Page 471 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C4.1. Descriptive characteristics of the randomized controlled trials and comparative cohort studies considered
relevant to KQ4 (continued)
Author, Year Study name Comparison Study Sample Inclusion criteria Population description: Quality
[Pubmed ID] /Database duration size (total) Age Comments
PSA (ng/mL)
Study design Tumor grade
Stage
Schapira 226 4 RP vs. RT vs. 3 and 12 113 (pre- ≥40 years of age, newly Age: 69 (45-85) yr C
2001 academically- expectant mo treatment) clinically localized prostate
11242319 affiliated management cancer (AJCC stage I or II). Median PSA (IQR) – Selection
Wisconsin 112 (3 mo) Exclusion criteria: Unable to RP: 7.6 (4.9-11.1) bias: 19%
Prospective hospitals, speak English, a clinical RT: 7.1 (4.9-12.3) eligible
cohort including 2 102 (1 yr) diagnosis of dementia, or unable EM: 7.9 (3.2-10.1) patients
VA Medical to verbally communicate. were not
Centers Dropouts: 6 patients died before Gleason score in RP, RT, and contacted
the end of the study due to EM groups, respectively- for a variety
complications from radiation 2-4: 30%, 16%, 23% of reasons;
proctitis and cystitis after 5-6: 49%, 51%, 54% dropout
prostate cancer treatment with 7: 19%, 29%, 8% rate 12%,
external beam radiation (n=1), 8-10: 3%, 4%, 15% 9%, 7% in
myocardial infarction (n=1), RP, RT,
bladder cancer (n=1), and TNM Stage: EM, T1, 55%; T2, and RM
undetermined causes (n=3). 45%. RP, T1, 55%; T2, 45%. group,
Other reasons for dropping out RT, T1, 43%; T2, 57% respectively
included geographic relocation
(n=4, development of a new an
serious illness (n=3),
progression of an underlying
comorbidity (n=1), and lost to
followup (n=7)

C-153